Skip to content

The effect of Sacubitril/valsartan On Long-term oUtcomes in nonparoxysmal atrial fibrillation paTients wIth adverse left atrial remOdeling after ablatioN (SOLUTION trial)

The Effect of Sacubitril/Valsartan on Long-term Outcomes in Nonparoxysmal Atrial Fibrillation Patients with Adverse Left Atrial Remodeling after Ablation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102523
Enrollment
Unknown
Registered
2025-05-15
Start date
2023-04-16
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibirllation

Interventions

ARNI group:After RFCA, ACEIs and ARNIs were administered to the control group and the ARNI group, respectively. The patients in the control group who experienced intolerable coughing symptoms due to A
control group:For patients in the control group, the initial dosage of 2-4 mg of perindopril or 40mg of valsartan once daily and the dosage can be doubled every 2-4 weeks until gradually titraed to th

Sponsors

Wujin Hospital Affiliated with Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Persistent atrial fibrillation (duration >7 days but 1 year); 2.Resistance to at least one antiarrhythmic drug; 3. Left atrial diameter (LAD) <=55 mm; 4. History of hypertension or hypertension at admission; 5. First-time atrial fibrillation ablation; 6. Those with poor left atrial substrate .

Exclusion criteria

Exclusion criteria: 1. Age 85 years; 2. Pregnancy or lactation in females; 3. Previous radiofrequency ablation or surgical intervention for arrhythmia; 4. Atrial fibrillation duration >5 years; 5. Significant structural heart disease (e.g., hypertrophic cardiomyopathy, dilated cardiomyopathy, severe valvular heart disease); 6. History of myocardial infarction; 7. Life expectancy <1 year; 8 Known hereditary angioedema or history of angioedema related to ACE inhibitors/ARBs and allergy to sacubitril/valsartan or its components; 9. Use of ARNI within the past week; 10. Inability to obtain informed consent.

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study was freedom from AF or AT/AFL 12 months postablation;

Secondary

MeasureTime frame
recurrence types;systolic blood pressure (SBP);diastolic blood pressure (DBP);left atrial internal diameter (LAD);left ventricular end-diastolic diameter (LVEDD);left ventricular ejection fraction (LVEF);NT-proBNP;major adverse cardiac events (MACEs);

Countries

China

Contacts

Public ContactWenhua Li

Wujin Hospital Affiliated with Jiangsu University

64641233@qq.com+86 139 1589 5326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026